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Abstract
Mitogen-activated protein kinase kinases (MKK or MEK) 1 and 2 are usually treated as redundant kinases. However, in
assessing their relative contribution towards ERK-mediated biologic response investigators have relied on tests of necessity,
not sufficiency. In response we developed a novel experimental model using lethal toxin (LeTx), an anthrax toxin-derived
pan-MKK protease, and genetically engineered protease resistant MKK mutants (MKKcr) to test the sufficiency of MEK
signaling in melanoma SK-MEL-28 cells. Surprisingly, ERK activity persisted in LeTx-treated cells expressing MEK2cr but not
MEK1cr. Microarray analysis revealed non-overlapping downstream transcriptional targets of MEK1 and MEK2, and indicated
a substantial rescue effect of MEK2cr on proliferation pathways. Furthermore, LeTx efficiently inhibited the cell proliferation
and anchorage-independent growth of SK-MEL-28 cells expressing MKK1cr but not MEK2cr. These results indicate in SK-
MEL-28 cells MEK1 and MEK2 signaling pathways are not redundant and interchangeable for cell proliferation. We conclude
that in the absence of other MKK, MEK2 is sufficient for SK-MEL-28 cell proliferation. MEK1 conditionally compensates for
loss of MEK2 only in the presence of other MKK.
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Introduction
The mitogen-activated protein kinase (MAPK) kinase (MEK)
pathway is highly activated in many cancers including melanoma.
Indeed, more than eighty percent of human melanomas harbor
somatic B-Raf or N-Ras mutations causing constitutive activation
of MEK1 and 2 [1,2]. Elevated MEK1 and 2 activities promote
melanoma tumorigenesis, angiogenesis, and progression
[3,4,5,6,7]. Conversely, biological and small molecule inhibitors
targeting MEK 1 and 2 inhibit melanoma cell proliferation and
xenograft tumor growth as well as metastasis [8,9,10,11].
Consequently, a great deal of effort has been placed on
developing inhibitors of MEK1 and 2 for therapeutic purposes
[12]. Despite this, MEK1/2 inhibitors have failed to meet
expectations in clinical trials owing to poor efficacy and
unexpected toxicities [13,14,15]. A better understanding of the
relative contributions of MEK1 and 2 may aid in the design of
more effective therapies for treating melanoma and other MEK-
dependent cancers.
MEK1 and 2 share greater than 85% amino acid homology in
their kinase domains. They are considered to have overlapping
and redundant functions since their only known substrates are the
mitogen-activated/extracellular signal-regulated protein kinase
(MAPK or ERK) 1 and 2. This conclusion is borne out by studies
showing inhibition of either MEK1 or MEK2 has no effect on cell
proliferation and combined inhibition of these kinases is required
before an effect is observed [16]. However, interpretation of these
results is confounded by evidence suggesting MEK1 and MEK2
are not redundant. For instance, MEK1 knockout mice are
embryonic lethal [17]. However, knockout of MEK2 has no effect
on mouse viability [18], suggesting that MEK1 and MEK2 are
differentially expressed during mouse embryogenesis. Still, others
have shown that shRNA-mediated MEK2 knockdown has much
stronger inhibitory effect on cell proliferation than MEK1 [19],
and in another context that MEK1 but not MEK2 is required for
experimentally-induced benign epidermal papilloma formation
[20]. However, in assessing the relative contribution of MEK1 and
MEK2 towards ERK-mediated biologic response each of these
studies has relied on tests of necessity, but not sufficiency. Since
independent observations have suggested cross talk between MKK
signaling pathways [21,22,23], redundancy of MEK1 and MEK2
may be dependent on co-operations of other MKK members, and
the difference between MEK1 and MEK2 may not be revealed
until the co-operations from other MKK members are blocked.
We designed two series of experiments to test the hypothesis
that the functions of MEK1 and MEK2 in SK-MEL-28 human
melanoma cells are critical and interchangeable for melanoma cell
proliferation. In the first experiment we used a traditional siRNA-
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signaling pathway for SK-MEL-28 cell proliferation. In this
experiment either MEK1 or MEK2 was knocked-down by the
specific siRNA while the other MEK isoform and other MKK
family proteins were expressed. In the second experiment we
developed a novel experimental system that allowed us to evaluate
the sufficiency of individual MEK signaling pathways for cell
proliferation. To do this, we took advantage of the MEK/MKK-
specific proteolytic activity of anthrax lethal toxin (LeTx) [24].
LeTx is a binary toxin secreted by the bacterium Bacillus anthracis.
It is composed of a binding moiety called protective antigen (PA)
and an enzymatic moiety, lethal factor (LF). During cellular
intoxication, PA binds to the anthrax receptors expressed on the
host cell surface and then is cleaved by a furin-like protease. This
cleavage removes a 20-kDa N-terminal fragment and leaves a 63-
kDa C-terminal truncation, PA63, on the cell surface. PA63 then
forms an oligomerized channel to which the LF binds. After the
binding of LF, the complex is internalized into cells through the
endosomal internalization pathway. The acidic environment of the
endosome causes a conformational change in PA63 that results in
the formation of pores through which LF is released into cytosol
(reviewed in [25]).
Since its initial identification as an MEK1/2-specific protease
[24], additional members of the MAP kinase kinase family,
including MKK3, 4, 6 and 7 but not MEK5, have also been found
to be substrates of LF ([26,27,28] and discussed in [29]). LF
specifically cleaves the N-terminus of MEK and other MKK
proteins at the consensus cleavage site: three to four basic or
proline residues followed by three variable residues followed by an
aliphatic residue: (B/P)3–4-(X)3-Al. The N-termini of this family of
proteins harbor MAP kinase docking sites that are required for the
interaction between MEK/MKK and MAPK [30]. Not surpris-
ingly, after LF cleavage, the C-terminal part of MEK/MKK,
which contains the kinase domain, loses its affinity for the
downstream MAP kinases [31,32]. In addition, biochemical
evidence has shown that loss of the amino terminus may
destabilize MEK, leading to the decreased intrinsic kinase activity
that is observed following LF-mediated proteolysis [31]. Thus,
cleavage of MEK/MKK by LF results in a blockade of not only
the ERK pathway but also of the p38 MAPK and JNK pathways.
We used LeTx to inhibit both MEK1 and MEK2 as well as
other MKK signaling pathways in SK-MEL-28 cells, and then
selectively rescued either MEK1 or MEK2 signaling by expressing
a cleavage-resistant form of MEK (MEKcr).
The results of these experiments lead us to conclude that in the
absence of other MKK, MEK2 is sufficient to drive SK-MEL-28
cell proliferation. MEK1 can conditionally compensate for loss of
MEK2 only in the presence of other MKK. Thus, our findings
indicate MEK1 and MEK2 signaling pathways possess non-
redundant biologic activities.
Results
Necessity of Individual MEK Signaling for Melanoma Cell
Proliferation
To test the hypothesis that MEK1 and MEK2 are redundant
and interchangeable for melanoma cell proliferation, we first
evaluated the necessity of MEK1 or MEK2 signaling for
melanoma cell proliferation by siRNA-mediated knockdown. To
do this, we transfected human melanoma SK-MEL-28 cells with
individual siRNAs or pools of siRNAs specifically targeting either
MEK1 or MEK2. SK-MEL-28 cells harbor the B-Raf_V600E
mutation [1], which promotes constitutive activation of MEK1
and MEK2, and the EGFR_P753S mutation [33]. As shown in
Figure 1, isoform-specific siRNAs efficiently knocked-down the
targeted MEK isoform without affecting the other. We found that
individual knock down of either MEK1 or MEK2 had no effect on
ERK activation in SK-MEL-28 cells. However, pooled siRNA
targeting both MEK1 and MEK2 did cause a decrease in ERK
phosphorylation (Figure 1). We also determined the necessity of
MEK1 or MEK2 signaling for cell cycle progression in SK-MEL-
28 cells using fluorescence-activated cell sorting. Under normal
cell culture condition, about 70% of SK-MEL-28 cells are in G0/
G1 phase. Whereas knock down of either MEK1 or MEK2 had no
effect on cell cycle progression (p.0.05), the combined knockdown
of MEK1 and MEK2 resulted in a 10% increase in cells at G0/G1
(p,0.0001) (Table 1). These data indicate that neither MEK1 nor
MEK2 signaling alone is necessary for ERK activation and cell
cycle progression in SK-MEL-28 cells, and that cells can
compensate for loss of either MEK1 or MEK2 to activate ERK
and to promote cell cycle progression in SK-MEL-28 cells. This
supports the hypothesis that MEK1 and MEK2 are interchange-
able for melanoma cell proliferation.
Point Mutations at the P19 Position Render MEK Resistant
to LF-mediated Cleavage
We reasoned that if MEK1 and MEK2 are functionally
redundant and interchangeable, they should have comparable
sufficiency for melanoma cell proliferation. For this purpose, we
sought to maintain only MEK1 or MEK2 activity while
simultaneously deactivating the other MEK isoform as well as
other MKK family proteins in melanoma cells. To achieve this, we
Figure 1. Necessity of MEK1 and MEK2 signaling pathways for
ERK activation in SK-MEL-28 cells. SK-MEL-28 cells were transfected
with nothing (N), lipid only (L), non-silencing control siRNA (NS), MEK-
specific siRNA (MEK1 siRNA 7, 8, 11, and MEK2 siRNA 9, and 14), pools of
MEK-specific siRNA (MEK1 siRNA 7+8+11 and MEK2 siRNA 9+14) or
combinations of pools of MEK1- and MEK2-specific siRNA (P1, MEK1
siRNA 8+11 plus MEK2 siRNA 9+14; P2, MEK1 siRNA 7+8+11 plus MEK2
siRNA 9+14) as described in Material and Methods. After transfection,
cells were trypsinized and split into separate dishes for cell lysate
collection and for cell cycle analysis (results shown in Table 1). Seventy-
two hours later, whole cell lysates were harvested and immunoblotted.
The efficiency of siRNA-mediated MEK knock down was examined by
immunoblotting with antibodies against MEK1 (top panel) or MEK2 (the
second panel). ERK activation was detected by antibodies against
phosphorylated ERK (the third panel). Total ERK expression was
detected by ERK antibody as a control (the fourth panel). Antibody
against GAPDH was used as a loading control (bottom panel).
doi:10.1371/journal.pone.0017165.g001
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endogenous MEK and MKK pathways were inhibited by LF
and MEK1 or MEK2 signaling was rescued by expressing a
mutant MEK that was engineered to be resistant to LF-mediated
proteolysis.
To make MEK resistant to LF-mediated cleavage, we altered
the hydrophobicity and the surface charge of the LF cleavage
sites by introducing an aliphatic-to-aspartic acid mutation to the
cleavage site at the 19 position (P19), which is critical for cleavage
by LF [31,34]. We fused a V5 tag to the NH2- termini of wild
type and the cleavage resistant form of MEK1 and MEK2
(MEK1cr and MEK2cr), and introduced these V5-MEK fusion
proteins into Chinese hamster ovary K1 (CHO K1) cells by
transfection. To confirm the LF-mediated cleavage of wild-type
V5-MEK and the cleavage resistance of V5-MEKcr, we treated
CHO K1 cells expressing V5-MEK or V5-MEKcr with LeTx,
and examined the integrity of V5-MEK and V5-MEKcr by
immunoblotting. As shown in Figure 2A, in control cells (none-,
mock-, and V5-lacZ-transfected cells), LeTx treatment resulted in
al o s so ft h eN H 2-terminal epitope (detected by an antibody
specifically recognizing MEK1 at the NH2- terminus) and a slight
increase in the electrophoretic mobility (detected by an antibody
recognizing MEK1 at the COOH-terminus) of endogenous
MEK1, demonstrating the MEK cleavage by LF in CHO K1
cells. In addition, LF-mediated proteolysis resulted in a loss of
NH2-terminal V5 epitope only in CHO K1 cells expressing wild-
type V5-MEK1 or V5-MEK2 but not in cells expressing V5-
MEK1cr or V5-MEK2cr (Figure 2B and 2C). The loss of the V5
epitope did not appear to be a result of decreasing CMV
promoter activity (due to the down regulation of c-jun and c-fos
by LeTx treatment) as the expression level of V5-lacZ in cells
remained unchanged in the presence of LF (Figure 2A). We
noticed a substantial increase in non-tagged MEK expression
accompanied V5-MEK transfection (Figure 2B and C, middle
panels). This was due to internal translation from the original
start codon of MEK sequence (see Text S1). Together, these
results demonstrate that MEK1cr and MEK2cr were resistant to
LF-mediated proteolysis.
Point mutations at the P19 site render other MKK
members resistant to LF-mediated cleavage
A similar strategy was used to generate cleavage-resistant forms
of MKK3, MKK4, MKK6 and MKK7. As expected, the
aliphatic-to-aspartic mutation at the P19 position rendered
MKK3 and MKK6 resistant to LF cleavage (Figure 2D). As
MKK4 and MKK7 were previously reported to harbor two LF
cleavage sites [27], two cleavage-resistant mutants with the
aliphatic-to-aspartic mutation introduced to one of the cleavage
sites were generated for each of MKK4 and MKK7: V5-
MKK4cr_46 and V5-MKK4cr_59 for MKK4, and V5-
MKK7cr_45 and V5-MKK7cr_77 for MKK7 (Figure 2E and
F). Since one of the cleavage sites remained unchanged, we
expected that these V5-MKK4cr and V5-MKK7cr mutants
should be still sensitive to LF cleavage. However, the aliphatic-
to-aspartic mutation was sufficient to make V5-MKK4cr_46 and
both of the V5-MKK7cr mutants resistant to cleavage (Figure 2E
and F).
LF cleaves human MKK4 at the Lys
45-Leu
46 position but
not the Arg
58-Phe
59 position in mammalian cells
Two possibilities can explain the unexpected observation of
MKK4 cleavage. First, LF cleaves MKK4 only at the Lys
45-Leu
46
position but not at the Arg
58-Phe
59 position (i.e., Arg
58-Phe
59 of
MKK4 is not a bona fide LF cleavage site). Alternatively, LF cleaves
MKK4 at both positions in a processive manner (i.e., cleavage at
Arg
58-Phe
59 requires a prior cleavage at Lys
45-Leu
46). To
distinguish between these two possibilities we constructed wild-
type human MKK4 fused with a V5 tag followed by a 66His tag
at the COOH-terminus (denoted as MKK4-V5-His6). In addition,
two MKK4-V5-His6 deletion mutants were constructed as
molecular weight indicators: MKK4 with a deletion of amino
acid residues 1–45 (denoted as MKK4_d45-V5-His6), and MKK4
with a deletion of amino acid residues 1–58 (denoted as
MKK4_d58-V5-His6). The MKK4_d45-V5-His6 deletion mu-
tant also allowed testing of the second possibility that LF cleaves
MKK4 at both sites in a processive manner. The set of these
proteins was then expressed in CHO K1 cells and in-cell cleavage
assays were performed. As shown in Figure 3, LeTx treatment of
CHO K1 cells expressing wild-type MKK4-V5-His6 resulted in a
complete loss of the V5 epitope, indicating MKK4 cleavage by LF.
However, under the same conditions we could not detect the LF-
cleaved COOH-terminal fragment of MKK4 using an anti-V5
antibody (Figure 3, lane 2). An explanation for this is that after LF
cleavage, the COOH-terminus of MKK4 is degraded. To test this,
MG-132, a proteosome inhibitor, was included in the in-cell
cleavage assay. As shown in Figure 3 (lane 4), MG-132 treatment
rendered the LF-cleaved COOH-terminus of MKK4 recognizable
by V5 antibody in the immunoblotting, indicating that after LF
cleavage MKK4 is degraded through a proteosome-dependent
pathway.
The two MKK4 deletion mutants, MKK4_d45-V5-His6 and
MKK4_d58-V5-His6, were distinguishable by the differential
electrophoretic mobility in an SDS-PAGE gel (Figure 3, lanes 5–8
and lanes 9–12 respectively). After LF cleavage, the COOH-
terminus of MKK4-V5-His6 (Figure 3, lane 4) had a similar
electrophoretic mobility as that of MKK4_d45-V5-His6 (Figure 3,
lane 5–8) but not MKK4_d58-V5-His6 (Figure 3, lane 9–12). In
addition, LeTx did not cause an electrophoretic mobility shift of
the MKK4_d45-V5-His6 deletion mutant. It is interesting to note
that levels of MKK4_d45-V5-His6 expression were substantially
elevated in the presence of MG-132 (Figure 3, lane 7 and 8). This
indicates that the MKK4_d45-V5-His5 deletion mutant is rapidly
Table 1. Percentage of G0/G1 population in MEK siRNA-
transfected SK-MEL-28 cells.
siRNA experiments
G0/G1 population
(% ± S.D.)
*
None 69.4560.91
Lipid only 69.6861.21
Non-silencing 70.4960.16
MEK1 siRNA-7 70.4563.27
MEK1 siRNA-8 71.3063.07
MEK1siRNA-11 70.4361.83
MEK1 siRNA-7811 72.9261.71
MEK2 siRNA-9 70.6560.48
MEK2 siRNA-14 71.2160.86
MEK2 siRNA-914 71.5361.24
P1 (MEK1 siRNA-811 + MEK2 siRNA-914) 81.3361.48
**
P2 (MEK1 siRNA-7811 + MEK2 siRNA-914) 78.2463.41
**
*Data were obtained from at least three independent experiments.
**p,0.0001, determined by one-way ANOVA followed by Bonferroni post-hoc
analysis.
doi:10.1371/journal.pone.0017165.t001
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17165Figure 2. Resistance of V5-MEKcr and V5-MKKcr to LF-mediated proteolysis. (A) Non-transfected (None), mock-transfected (Mock) and V5-
lacZ-transfected CHO K1 cells as well as cells transfected with (B) wild-type V5-MEK1 or V5-MEK1cr, (C) wild-type V5-MEK2 or V5-MEK2cr, (D) wild-type
V5-MKK3, V5-MKK3cr, wild-type V5-MKK6, or V5-MKK6cr, (E) wild-type V5-MKK4 or V5-MKK4cr, and (F) wild-type V5-MKK7 or V5-MKK7cr were treated
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LeTx-cleaved full length protein. Together these results demon-
strate MKK4 is cleaved by LF only at the Lys
45-Leu
46 position but
not the Arg
58-Phe
59 position.
MKK7 is not a preferred LF substrate in some mammalian
cells
When we tested the cleavage resistance of V5-MKK7cr_45
and V5-MKK7cr_77 mutants, we found both of the mutants
were resistant to the cleavage in CHO K1 cells (Figure 2F).
However, under the same conditions we were unable to detect
convincing cleavage of wild-type MKK7 (Figure 2F). One
possible explanation for this is that the amount of LF was
insufficient to cleave the excess of V5-MKK7 that was expressed.
To test this, a decreasing amount of the plasmid DNA encoding
for wild-type V5-MKK7 was transfected into CHO K1 cells and
the cleavability of MKK7 was tested in cells in the presence of
cycloheximide. Under these conditions, the expression level of
wild-type V5-MKK7 was decreased in proportion to the amount
of the plasmid DNA transfected (Figure 4A, upper panel).
However, LF was unable to cleave wild-type V5- MKK7 even
when its expression was decreased to a barely-detectable level. As
a positive control for LF activity we probed the same lysates with
antibodies against the NH2-terminus of MEK1 and observed that
MEK1 was cleaved by LF (Figure 4A, middle panel). Moreover,
we examined the LF cleavage of endogenous MKK7 in 293FT
cells (which are derived from human embryonic kidney 293 cells)
using an antibody specifically recognizing the last 20 amino acid
of human MKK7. We observed that the endogenous MKK7 in
293FT cells was still intact even when the cells were treated with
LeTx for 72 h (Figure 4B). Collectively this result indicates that
MKK7 is not a preferred substrate of LF in CHO K1 and 293FT
cells.
Expression and activity of Cleavage-resistant MEK1 or
MEK2 in SK-MEL-28 Cells
To verify cleavage resistance in melanoma cells we established
human melanoma SK-MEL-28 cell lines stably expressing V5-
MEK1cr or V5-MEK2cr, or the wild-type counterparts. We
treated these cells with LeTx, and then examined the cellular levels
with PA alone (PA) or LeTx for 12 h as described in Materials and Methods. Total cell lysates were then harvested and immunoblotted with the
antibodies indicated to the right of each panel. V5 antibody and an antibody against NH2-terminus of MEK1 were used to detect loss of NH2-terminal
epitopes following LF-mediated proteolysis. Antibodies against the COOH-terminus of MEK1, MEK2, MKK3, and MKK6 were used to detect increased
electrophoretic mobility of cleaved MEK/MKK fragments. Antibodies against a-tubulin, b-tubulin, and a-actin were used as equal loading controls.
doi:10.1371/journal.pone.0017165.g002
Figure 3. In-cell cleavage of MKK4 by LF. CHO K1 cells were
transfected with MKK4-V5-His6, MKK4_d45-V5-His6, or MKK4_d58-V5-
His6 plasmids. After transfection, cells were split to four dished and
cultured for 12 h. Cells in each dish were treated with PA alone (1 mg/ml
PA) or LeTx (1 mg/ml PA plus 0.1 mg/ml LF) in the presence of 0.1%
DMSO or 10 mg/ml MG-132 for 24 h. Total cell lysates were collected
and immunoblotted with antibodies against V5 epitope (top panel) and
GAPDH (bottom panel).
doi:10.1371/journal.pone.0017165.g003
Figure 4. MKK7 is not a preferred LF substrate in mammalian
cells. (A) Non-transfected (None) CHO K1 cells and cells transfected
with a decreasing amount of V5-MKK7 plasmids (8, 4, 2, and 1 mga s
indicated) were treated with PA alone (PA) or LeTx for 12 h in the
presence of cycloheximide as described in Material and Methods. Total
cell lysates were collected and immunoblotted with antibodies against
V5 epitope (top panel), NH2-terminus of MEK1 (middle panel), and b-
actin (bottom panel). (B) To determine whether endogenous MKK7 was
cleaved by LF in mammalian cells, 293FT cells were treated with PA
alone (PA) or LeTx for 24, 48, and 72 h (indicated). Total cell lysates were
collected and immunoblotted with antibodies against the last 20 amino
acids of human MKK7 (top panel), NH2-terminus of MEK1 (middle
panel), and b-actin (bottom panel).
doi:10.1371/journal.pone.0017165.g004
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ysis caused loss of the NH2-terminal V5 epitope in cells expressing
wild-type V5-MEK1 and V5-MEK2 within 24 hours even when
the cells were treated with low concentrations of LF (1 ng/ml)
(Figure 5, top panel). In contrast, V5-MEK1cr and V5-MEK2cr
were resistant to LF-mediated cleavage and showed only partial
cleavage by LF at the highest concentrations used (100 ng/ml)
(Figure 5, top panel).
Cleavage by LF removes an NH2-terminal docking domain that
is required for MEK interaction with MAPKs [30,31,32]. To
confirm that neither the addition of the V5 tag nor the
introduction of the LF cleavage-resistant mutation interferes with
MEK’s ability to interact with and phosphorylate ERK, we
examined the activity of V5-MEK1cr and V5-MEK2cr. SK-
MEL-28 cells harbor the B-Raf_V600E mutation [1], which
promotes constitutive activation of MEK1 and MEK2. When we
examined the status of cellular V5-MEK1cr and V5-MEK2cr by
immunoblotting using an antibody that only recognized phos-
phorylated (activated) MEK1 and MEK2, we found that the
activation status of V5-MEKcr proteins were comparable to their
wild-type counterparts (Figure 6A). This indicates that V5-
MEK1cr and V5-MEK2cr are actively signaling in SK-MEL-28
cells. Further, we immunoprecipitated V5-MEK1cr and V5-
MEK2cr from SK-MEL-28 cells and then performed in vitro kinase
assays using recombinant ERK2 as a substrate. Taking into
consideration the amount of protein used for each assay,
immunoprecipitated V5-MEK1cr and V5-MEK2cr were as
capable as their wild-type counterparts of phosphorylating
ERK2 (Figure 6B). These results indicate that neither the addition
of the V5 tag nor the introduction of the cleavage-resistant
mutation alters the ability of MEK to interact with and
phosphorylate ERK. Collectively these data demonstrate we can
use this model to experimentally isolate either the MEK1 or
MEK2 signaling pathway from other MKK signaling pathways in
melanoma SK-MEL-28 cells.
MEK2, but not MEK1, is Sufficient to Maintain ERK Activity
ERK1 and ERK2 are the only identified enzymatic substrates
of MEK1 and MEK2. To evaluate the sufficiency of MEK1 and
MEK2 to phosphorylate ERK in SK-MEL-28 cells, we examined
the status of ERK phosphorylation when these cells had only
MEK1 or MEK2 (Figure 5, second and third panels). ERK2
activation was inhibited by LeTx in SK-MEL-28 parental cells as
well as in cells expressing wild-type V5-MEK1 or wild-type V5-
MEK2 (Figure 5, fourth panel). In contrast, V5-MEK2cr
maintained ERK2 phosphorylation in the presence of LeTx.
However, ERK2 phosphorylation was not maintained in V5-
MEK1cr-expressing cells treated with LeTx. These results
indicate that MEK2, but not MEK1, is sufficient to maintain
ERK2 activity in the presence of LF, and that MEK1 and MEK2
are not interchangeable for ERK2 activation in this cellular
context.
Genome-wide cDNA Microarray Reveals Non-overlapping
Transcriptional Signatures of MEK1 and MEK2
MAP kinase pathways regulate gene expression at the
translational and/or post-translational level. To identify the
transcriptional targets of MEK1 and MEK2 we isolated mRNA
from MEKcr-expressing SK-MEL-28 cells treated with LeTx.
V5-lacZ-expressing cells treated with protease inactive LeTx (PA
plus LF_E687C, an inactive LF mutant) or active LeTx were
used as controls. Under this treatment condition, either MEK1 or
MEK2 was expressed in MEKcr-expressing cells (Figure S1).
Using the Agilent 60-mer Whole Human Genome Microarrays,
we compared the gene expression patterns in these cells. We
found that compared with inactive LeTx controls, treatment, of
Figure 5. Individual MEK signaling in LeTx-treated SK-MEL-28 cells. SK-MEL-28 parental cells and cells stably expressing V5-MEK or V5-MEKcr
were treated with LeTx (1 mg/ml PA plus 0, 1, 10, or 100 ng/ml LF) for 24 h. Total cell lysates were then harvested and immunoblotted with antibodies
against the V5 epitope to confirm the cleavage resistance of V5-MEKcr (top panels). Antibodies against the carboxyl terminus of MEK1 (second panel)
and the carboxyl terminus of MEK2 (third panel) were used to demonstrate individual MEK expression in LeTx-treated cells. Antibodies against
phospho-ERK1/2 (fourth panel) and total ERK1/2 (fifth panel) were used to examine ERK activation, and an antibody against b-actin and b-tubulin
were used as a loading control (bottom panels).
doi:10.1371/journal.pone.0017165.g005
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significant changes in expression of 2,560 genes out of 18,359
represented on the microarray. Of these 2,560 genes, 268 can be
rescued in V5-MEK1cr-expressing cells, while 1,214 can be
rescued in V5-MEK2cr-expressing cells (Figure 7). In examining
the transcriptional profiles of each MEK we reasoned that if
MEK1 and MEK2 were redundant and interchangeable,
transcriptional targets downstream of MEK1 and MEK2 should
overlap. In contrast, if MEK1 and MEK2 were not redundant,
they should have non-overlapping transcriptional footprints.
Consistent with the latter hypothesis we found that the
transcriptional footprints of MEK1cr and MEK2cr only partially
overlapped. Of note, we found that MEK1cr and MEK2cr
affected expression of genes that were not altered by LeTx
treatment (see comments in discussion). These observations
indicate that in this experimental system MEK1 and MEK2
have both overlapping and non-overlapping transcriptional
targets.
MEK2cr, but not MEK1cr, Rescued Proliferation-related
Pathways in LeTx-treated Cells
We further examined the gene expression data to identify
pathways that may be differentially regulated by MEK 1 and
MEK2 in LeTx-treated cells by performing a gene set enrichment
analysis [35,36]. LeTx treatment resulted in down-regulation of
several transcriptional signatures, most of which were prolifera-
tion-related pathways, such as pathways of E2F transcription
factor, RNA processing, DNA replication and recombination, and
cell cycle progression, as well as oncogenic pathways (e.g. Myc).
This supports the previous findings that LeTx inhibits melanoma
cell proliferation in vitro [10,11]. Interestingly, 51 of these
transcriptional signatures were uniquely rescued in V5-MEK2cr-
expressing cells while no signatures appeared to be uniquely
rescued by V5-MEK1cr-expressing cells (Table 2 and Table S1,
for Table S1 references please see References S1). This finding
indicates that MEK2, but not MEK1, is sufficient for expression of
genes associated with cell proliferation.
Figure 6. Activity of V5-MEKcr. (A) Phosphorylation and activation of V5-MEKcr in cells. Parental SK-MEL-28 cells and cells stably expressing V5-
MEK or V5-MEKcr were treated with PA alone (PA) or LeTx for 24 h. Whole cell lysates were then prepared and immunoblotted with anti-phospho
MEK1/2 antibody to examine the phosphorylation status of V5-MEK1cr and V5-MEK2cr in SK-MEL-28 cells (upper panel), or anti-GAPDH antibody for
equal loading control (lower panel). (B) Kinase activity of V5-MEKcr. Anti-V5 immunoprecipitates were prepared from SK-MEL-28 cells and then used
for in vitro kinase assays (top panels) in the presence or absence of active B-Raf and/or recombinant ERK2. The proteins were then separated in 10%
Tris-Glycine gels, and ERK2 phosphorylation was visualized by using a FLA-5000 PhosphoImager. Equal amount of V5 immunoprecipitates were
immunoblotted for V5 (bottom panel) as a V5-MEK input control.
doi:10.1371/journal.pone.0017165.g006
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Proliferation
Previous studies have shown the inhibitory effect of LeTx on
melanoma cell proliferation in vitro [10,11]. To determine whether
MEK1 or MEK2 was sufficient for melanoma cell proliferation,
we examined the sensitivity of V5-MEKcr-expressing SK-MEL-28
cells for LeTx. To do this, we selected 3 independent stable clones
displaying different levels of V5-fusion protein expression from
each of the stably transfected SK-MEL-28 cell lines (Figure S2).
We tested each of these cell lines for their sensitivity to LeTx in vitro
by treating the cells with various concentrations of LF (Figure S3).
We observed that whereas parental SK-MEL-28 cells and the cells
Figure 7. Global gene expression profiles downstream of MEK1 and MEK2. Two sets of SK-MEL-28 parental cells and the cells stably
expressing V5-lacZ, V5-MEK1, V5-MEK1cr, V5-MEK2, or V5-MEK2cr were treated with control (PA plus LF_E687C) or LeTx for 24 h as described in
Material and Methods. Total cell lysates were collected from cells in one of the sets for immunoblotting (see Figure S1). Total RNA samples were
collected from the other set of cells and subjected to cDNA microarray hybridization and data analysis as described in Material and Methods. The
gene expression profile in control-treated V5-lacZ-expressing cells was compared to that in LeTx-treated cells to generate a list of genes that were
significantly changed by LeTx treatment (shaded circle). The lists of genes that were significantly rescued by V5-MEK1cr (solid circle) or MEK2 (dashed
circle) were generated by comparing the gene expression profile in LeTx-treated V5-lacZ-expressing cells with LeTx-treated V5-MEK1cr-expressing
cells or LeTx-treated V5-MEK2cr-expressing cells, respectively. The numbers of genes that were significantly changed are labeled.
doi:10.1371/journal.pone.0017165.g007
Table 2. Transcriptional signatures that are down regulated by LeTx treatment and significantly rescued by MEK2cr.
t-statistics
b
Signatures/Pathways/Gene sets
a V5-lacZ V5-MEK1cr V5-MEK2cr Reference
c
Myc 27.14 0.32 4.53 Ref. [51]
E2F1, TFDP1, RB1 transcription factors 26.28 1.07 3.29 MSigDB Gene Set: SGCGSSAAA_V$E2F1DP2_01
rRNA processing 25.44 0.33 2.74 GO: 0006364
Ribosome biogenesis 26.46 0.67 3.80 GO: 0042254
DNA recombination 25.00 1.39 3.30 GO: 0006310
Nucleotidyl-transfer reaction 23.63 1.39 2.93 Ref. [52]; MSigDB Gene Set: Nucleotidyltransferase_activity
G1/S cell cycle transition 23.67 1.49 2.77 MSigDB Gene Set: G1PATHWAY
aThe complete list of transcriptional signatures is presented in Table S1.
bt-statistics were obtained from three independent microarray experiments, and the scores in MEK1cr-expressing cells have p values greater than 0.005.
cMSigDB Gene Sets: http://www.broadinstitute.org/gsea/msigdb/search.jsp; GO (Gene Ontology): http://www.geneontology.org/; Cancer gene modules: http://robotics.
stanford.edu/,erans/cancer/browse_by_modules.html.
doi:10.1371/journal.pone.0017165.t002
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similar sensitivity to LeTx, cells expressing V5-MEK2cr showed a
significantly lower sensitivity to LeTx-induced proliferation
inhibition in vitro (Figure 8 and Figure S3C). Importantly, the
resistance of V5-MEK2cr-expressing cells to LeTx positively
correlated with expression levels of V5-MEK2cr. The IC50 of LF
on SK-MEL-28 cells expressing low, moderate and high levels of
V5-MEK2cr was 3, 8, and 21 fold higher than that for parental
cells, respectively (Figure 8 and Figure S3C). In addition, we
reasoned that if resistance to LF is strictly dependent upon
expression of V5-MEK2cr, then these cells should retain their
sensitivity to small molecule allosteric inhibitors of MEK.
Consistent with this, V5-MEK2cr-expressing cells were as sensitive
as other V5-MEK-expressing cells to the MEK inhibitors U0126
and PD184352 (Figure 8). These data demonstrate that the
cleavage-resistant form of MEK2, but not MEK1, is sufficient to
drive SK-MEL-28 cell proliferation in the presence of LeTx, and
that MEK1 and MEK2 signaling are not interchangeable for
melanoma cell proliferation.
It was recently reported that cross talk between ERK and p38
MAPK stimulates melanoma proliferation [23]. However, we
were unable to detect active p38 MAPK in SK-MEL-28 cells by
immunoblotting (data not shown). Furthermore, when we treated
SK-MEL-28 cells stably expressing V5-MKK3cr or V5-MKK6cr
with LeTx we observed that none of these stable cell lines was
resistant to LeTx (Figure S4). These observations indicate that
unlike MEK2, MKK3 and MKK6 are not sufficient for
melanoma cell proliferation.
MEK2 is Sufficient for Anchorage-independent Growth
We next tried to test the sufficiency of individual MEK1 and
MEK2 signaling pathways for tumor growth in vivo. However, in
xenograft experiments using athymic nude mice we observed that
tumors obtained with this model had substantially diminished
expression of V5-MEK1cr or V5-MEK2cr (data not shown). This
suggests that over-expression of MEK1 or 2 does not provide a
selective growth advantage for SK-MEL-28 xenograft tumors in
vivo. As an alternative approach we evaluated the ability of these
cells to grow in an anchorage independent fashion using soft agar
colony assays. Parental SK-MEL28 cells and cells expressing V5-
lacZ, V5-MEK or V5-MEKcr readily formed colonies (.50 mm
diameter) within 21 days (Figure 9A, top panels). However, in the
presence of LeTx colony formation of all cell types tested with the
exception of the cells expressing V5-MEK2cr was inhibited
(Figure 9A, lower panels). When these results were quantified we
noted that expression of V5-MKK2cr in SK-MEL-28 cells
Figure 8. Sensitivity of SK-MEL-28 cells to LeTx and MEK inhibitors. SK-MEL-28 parental cells and the cells stably expressing V5-lacZ, low (L),
moderate (M) or high (H) levels of wild-type V5-MEK or V5-MEKcr were tested for their sensitivity to LeTx, U0126 and PD184352 by performing in vitro
proliferation assays as described in Materials and Methods. (A set of representative proliferation curves is presented in Figure S3). IC50 values for each
stable cell line were normalized to the IC50 in parental cells. Results are presented as an average of fold change (X axis) of at least three independent
experiments 6 standard deviation (error bars). Statistical significance of data was performed using one-way ANOVA followed by post-hoc analysis. P
values were greater than 0.05 except for (*) p,0.005 and (**) p,0.00001.
doi:10.1371/journal.pone.0017165.g008
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LeTx (Figure 9B). This result demonstrates that MEK2 signaling is
sufficient for anchorage-independent growth of SK-MEL-28 cells.
Discussion
The mitogen-activated protein kinase kinase (MKK) signaling
pathways are a group of related protein kinase signaling cascades
that are widely expressed in eukaryotes including fungi, plants and
animals [37,38,39,40,41]. For epistemological reasons, MKK
signaling pathways have been organized into modules, each of
which contains a three tiered kinase cascade comprising a MKK
kinase, a MEK or MKK, and a MAPK. This paradigm has
shaped our perspective of these pathways so that they are most
frequently regarded as distinct. However, it is apparent there is
robust cross talk between the MKK signaling pathways (see for
example Xia et al., [21], MacKeigan et al., [22], Estrada et al., [23])
and cellular responses to stimuli may result from the coordinated
activities of multiple MKK pathways. For this reason we believe it
is important to consider potential pathway interactions when
evaluating the biologic function of these proteins.
We followed two complementary approaches to test the
hypothesis that the functions of MEK1 and MEK2 are critical
and interchangeable for SK-MEL-28 melanoma cell proliferation.
In the first series of experiments MEK-directed siRNAs were used
to selectively knock-down either MEK1 or MEK2, or both, in
human melanoma SK-MEL-28 cells to determine the necessity of
individual MEK signaling pathway for melanoma cell prolifera-
tion. In these experiments we found that simultaneous knockdown
of both MEK1 and MEK2 was required to inhibit ERK activation
and to block cell cycle progression. This indicates that neither
MEK1 nor MEK2 alone is necessary for these activities in
melanoma cells and supports our initial hypothesis that MEK1
and MEK2 are interchangeable for melanoma cell proliferation.
Other studies support the hypothesis that MEK1 and MEK2 are
functionally interchangeable. For example, Scholl et al., show that
Figure 9. Sufficiency of MEK2 signaling pathway for anchorage-independent growth of SK-MEL-28 cells. SK-MEL-28 parental cells and
cells stably expressing V5-lacZ or high levels of wild-type V5-MEK or V5-MEKcr were seeded as single-cell suspensions in soft agar and then treated
with PA alone control or LeTx, as described in Materials and Methods. After treatment (21 days), colonies were fixed and stained with 1% crystal violet
prepared in 10% ethanol. (A) Representative images of colonies grown in soft agar in the presence of PA alone or LeTx. Bars, 1 mm. (B) Anchorage-
independent growth was quantified, and the colony density was determined by dividing the number of colonies by the area and then normalizing to
the colony density of the parental cells treated with PA alone. One-way ANOVA followed by post-hoc analysis were performed to determine statistical
significance. P values were greater than 0.05 except for (*), p,0.00001.
doi:10.1371/journal.pone.0017165.g009
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epidermal hyperplasia to a similar extent [42]. However, these
studies evaluated necessity, but not sufficiency. Cross talk between
MKK pathways may mask the potential non-redundancy of
MEK1 and MEK2, which may not be revealed until the cross talk
is eliminated. As an alternative approach we developed a novel
experimental system utilizing the specific proteolytic activity of
anthrax lethal toxin to evaluate the sufficiency of individual
MEK/MKK signaling pathways for specific phenotypes or
cellular functions. This system is applicable to most mammalian
cells because anthrax toxin receptors are ubiquitously expressed in
many different types of cells [43,44]. With an appropriate
phenotype as a readout (e.g. proliferation in this study), this novel
system is a powerful tool allowing the dissection of the individual
roles of MEK/MKK signaling pathways. Since LF efficiently
cleaves and inactivates multiple MKK this experimental approach
eliminates not only the possible signaling by residual non-targeted
kinase molecules persists, but also ensures there is no cross talk
between MKK families.
While developing this model we made two important
observations that alter our viewpoint on LF activity. First, we
observed MKK4 underwent proteosome-mediated degradation
following cleavage by LF. This post-cleavage degradation may not
be limited to MKK4 since we noted loss of carboxy-terminal
epitope following cleavage for MEK1, MEK2, MKK3, and
MKK6 (Figure 2). Based on this we speculate that proteolysis by
LF destabilizes MEK/MKKs, perhaps by exposing an aliphatic
residue at the NH2- terminus [45], rendering them susceptible to
proteosomal degradation. Second, we observed in CHO K1 cells
that LF cleaves MKK4 only at the Lys
45-Leu
46 position but not
the Arg
58-Phe
59 position, and that LF does not cleave exogenously
expressed MKK7 in CHO K1 cells. Similarly, endogenous
MKK7 was not cleaved in human 293FT cells. This was
unexpected since it was reported earlier that all members in the
MKK family with the exception of MEK5 were substrates of LF
and that MKK4 and MKK7 each harbor two LF cleavage sites
[27]. However, whereas the earlier reports were based on in vitro
cleavage assays using recombinant protein substrate, our results
are based on in-cell cleavage assays. Thus it appears that certain
cells provide an environment that restricts LF activity, perhaps by
limiting substrate accessibility or by masking the cleavage site, and
blocks MKK7 proteolysis.
Interesting and novel observations regarding MEK function
also arose from this approach. First, in contrast to our siRNA
knockdowns, we found that reconstituting the activity of MEK2,
but not MEK1, was sufficient to drive proliferation of SK-MEL-28
cells. This indicates that MEK1 and MEK2 are not functionally
redundant. The results obtained from the necessity study (MEK
siRNA) and sufficiency study (LeTx and MEKcr) are not actually
contradictory as the two experimental systems model fundamen-
tally different cellular contexts. To explain these results, we
propose that while MEK2 alone is sufficient for SK-MEL28
melanoma cell proliferation, MEK1 can compensate for loss of
MEK2 only in the presence of an as yet unidentified factor. This
factor is likely an MKK (but not MEK5) or is regulated by an
MKK since the sufficiency of MEK2 is revealed only in the
presence of LF, a MEK/MKK-specific protease. However, this
factor likely is neither p38 MAPK nor JNK since the basal
activities of these kinases in SK-MEL-28 cells are below the limit
of detection by immunoblotting. In addition, we do not exclude
the possibility that this factor may be an as yet unidentified LF
substrate. Identification of this LF-sensitive factor may have
important clinical consequences since its targeted inactivation
would block the ability of MEK1 to compensate for loss of MEK2
activity and as a consequence increase the dependency on
proliferation signaling through MEK2.
The second novel observation arising from this approach was
that the transcriptional activities induced by MEK1 and MEK2
were not wholly contained within the LeTx-transcriptional
footprint (Figure 7). Since LeTx is a pan MKK inhibitor we
expected the result of expression of MEK1cr or MEK2cr would be
to relieve a sub-set of LeTx-induced transcriptional changes.
However, we found that MEK2cr, and to a lesser extent MEK1cr
altered the expression of genes that were unaffected by LeTx.
These results may be caused by exogenous expression of MEK2.
Alternately, the basal expression levels of these genes may be
subject to antagonistic regulation by MEK and at least one of the
other MKKs in normal cell culture condition. Changes in
expression of these genes are revealed when this co-regulation is
imbalanced (when cells have only individual MEK but not other
MKKs). There are several examples of MKK-related antagonistic
co-regulation in the literature. For example, survival of differen-
tiated rat PC-12 pheochromocytoma cells in culture is dependent
upon the presence of nerve growth factor (NGF) and removal of
NGF from the medium causes an increase in the activities of p38
MAPK and JNK which is necessary and sufficient to induce
apoptosis [21]. Interestingly, a decrease in ERK activity
accompanies NGF withdrawal and expression of constitutively
activated MEK1 prevents apoptosis induced by NGF withdrawal.
These results indicate that apoptosis in NGF-differentiated PC-12
cells is regulated by opposing activities of ERK and p38 MAPK/
JNK. Similar results have been obtained for paclitaxel-mediated
apoptosis of transformed cells [22].
In summary, using two complementary experimental approach-
es we have tested the redundancy of MEK1 and MEK2 signaling
in the in vitro proliferation of SK-MEL-28 melanoma cells. We
observed that MEK2, and not MEK1, is sufficient for cell
proliferation. However, MEK1 can compensate for the loss of
MEK2 activity in the presence of an unidentified factor. Our study
provides novel insight into the complicated interplay between
MEK1 and MEK2 that may have significant clinical impact for
treatment.
Materials and Methods
Cell lines and stable cell line establishment
Chinese hamster ovary (CHO) K1 cells were purchased from
American Type Culture Collection (Manassas, VA) and grown in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% FBS and 50 units/ml penicillin/streptomycin. SK-
MEL-28 cells were obtained from CeeTox Inc. (Kalamazoo, MI)
and grown in Roswell Park Memorial Institute (RPMI) 21640
medium supplemented with 5% FBS and 50 units/ml penicillin/
streptomycin. 293FT cells were purchased from Invitrogen
(Carlsbad, CA) and cultured in DMEM supplemented with 10%
FBS and 50 units/ml penicillin/streptomycin. Cells were cultured
at 37uC in a humidified 5% CO2 incubator. To establish stable
cell lines, SK-MEL-28 cells were transfected with V5-MEK, V5-
MEKcr or V5-lacZ control expression vectors by using Lipofecta-
mine 2000
TM (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Clonal stable transfectants were
selected against GeneticinH. Expression levels of V5-fusion
proteins in each stable clone were determined by immunoblotting.
siRNA-mediated MEK knock down
Multiple siRNAs specifically against human MEK1 or MEK2
and AllStars non-silencing control siRNA were purchased from
QIAGEN Inc. (Valencia, CA). To deliver siRNA into SK-MEL-
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TM Lipid (Bio-Rad, Hercules, CA) as
the transfection reagent. To do this, SK-MEL-28 cells (3610
5
cells) were seeded in 60-mm dishes. The next day, cells were
washed three times with PBS and covered with 1.6 ml of OPTI-
MEMHI (Invitrogen, Carlsbad, CA), to which siRNA:Lipid
complexes (prepared as described below) were then added. To
prepare siRNA:Lipid complexes, 10 ml of lipid was added into
30 ml of OPTI-MEMHI and incubate at room temperature for five
minutes. The prepared lipid was then added into 360 ml of OPTI-
MEMHI containing 100 pmole of each control or MEK siRNAs
plus 100 pmole of AlexaFluor488-conjugated non-silencing
siRNA, and incubated at room temperature for 20 minutes to
allow siRNA:Lipid complexes form. Eight hours after addition of
siRNA:Lipid complexes, cells were then trypsinized and split to
two 60-mm dishes and culture in DMEM containing 10% FBS
and 50 units/ml penicillin/streptomycin for 72 hours. At this time
point, AlexaFluor488 fluorescence could be observed in greater
than 95% of transfected cells under a fluorescence microscope
(data not shown), indicating that siRNAs were delivered into the
cells. Cells were harvested for immunoblotting and cell cycle
analysis.
Cell cycle analysis
Cellcycleprofile was assessed by fluorescence-activated cell sorting
as previously described [46]. Percentages of cells in G0/G1 phase of
cell cycle were measured using FACSCalibur software program.
Statisticalanalysisofdatawasperformedbyone-wayANOVA(www.
physics.csbsju.edu/stats/anova_NGROUP_NMAX_form.html)
followed by post-hoc analysis (http://graphpad.com/quickcalcs/
posttest1.cfm).
V5-MEKcr and V5-MKKcr constructions
Human MEK1 (NM_002755.2) sequence was PCR-amplified
from the pREST-A/MKK1 vector, which was a generous gift
from Natalie Ahn [47]. Human MEK2 (NM_030662.2), MKK3
(NM_145109.2), MKK4 (NM_003010.2), and MKK6
(NM_002758.2) sequences were PCR-amplified from the
I.M.A.G.E. clones (Open Biosystems, Huntsville, AL): MEK2,
clone #2961198; MKK3, clone #5215093; MKK4, clone
#5272439; MKK6, clone #4499772. Human MKK7
(NM_145185.2) sequences were PCR-amplified from the
pcDNA3/MKK7 vector. Amplified sequences were then inserted
into pENTR
TM Directional TOPOH vector (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. To generate
MEKcr/MKKcr, aspartic acid residues were introduced into the
P19 position of LF cleavage sites (the 9
th,1 1
th,2 7
th and 15
th amino
acid of MEK1, MEK2, MKK3 and MKK6, respectively; the 46
th
and 59
th amino acids of MKK4; 45
th and 77
th amino acids of
MKK7.) by using QuikChangeH Site-Directed Mutagenesis
(Agilent, Santa Clara, CA). All the wild-type MEK/MKK and
MEKcr/MKKcr sequences were verified by DNA sequencing.
V5-MEK/MKK mammalian expression vectors were created by
performing LR recombination reactions to move MEK/MKK
sequences from the Entry vectors to the pcDNA3.1/nV5-DEST
Destination vectors (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions.
Constructions of MKK4-V5-His6 and the deletion mutants
To make MKK4 carboxyl terminal fusion, the stop codon of
MKK4 sequence was removed from the MKK4 Entry vector by
using QuikChangeH Site-Directed Mutagenesis (Agilent, Santa
Clara, CA) with modified PCR reaction in which 10% DMSO was
included to solve secondary structure. A second run of modified
Site-Directed Mutagenesis reaction was performed to remove
amino acid 2–45 and 2–58 of MKK4 from the modified Entry
vector in order to generate the deletion mutant MKK4_d45 and
MKK4_d58, respectively. The coding regions of MKK4 on all the
Entry vectors were verified by DNA sequencing. MKK4-V5-His6
mammalian expression vectors were created by performing LR
recombination reactions to move MKK4 sequences from the
modified Entry vectors to the pcDNA-DEST40 Destination
vectors (Invitrogen, Carlsbad, CA) according to the manufactur-
er’s instructions.
In-cell MKK/MEK cleavage assay
To confirm the cleavage resistance of MEKcr and MKKcr, we
performed cleavage assays in CHO K1 cells. To do this, cells were
transfected with V5-MKK/MEK or V5-lacZ expression vectors by
Lipofectamine
TM 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. After transfection, cells were
trypsinized and split into two dishes, and each was then treated
with either control (1 mg/ml PA) or LeTx (1 mg/ml PA and
0.1 mg/ml LF) in the presence of 10 mg/ml cycloheximide (Sigma,
St. Louis, MO). PA and LF were expressed in an attenuated strain
of Bacillus anthracis (BH445) and purified by fast pressure liquid
chromatography as described [48]. Total cell lysates were collected
in RIPA lysis buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 2 mM Na3VO4, 20 mM sodium
pyrophosphate, 1% sodium deoxycholate, 1% Triton X-100,
0.1% SDS, and 16EDTA-free protease inhibitor cocktail (Roche,
Indianapolis, IN)] and homogenized by sonication. Protein
concentrations were determined by BCA
TM Protein Assay Kit
(Pierce, Rockford, IL) according to the manufacturer’s instruc-
tions. Lysates were then prepared in 16SDS sample buffer. Five
micrograms of total cell lysates were subjected to immunoblotting
to detect LF-mediated cleavage as described in the results.
LF cleavage of MKK4 and MKK7 in mammalian cells
To determine MKK4 cleavage by LF in mammalian cells,
MKK4-V5-His6 and the deletion mutants were transfected into
CHO K1 cells by Lipofectamine
TM 2000 (Invitrogen, Carlsbad,
CA). After transfection, cells were split into four dished and
cultured for 12 h. Cells in each dish were treated with PA alone
(1 mg/ml PA) or LeTx (1 mg/ml PA plus 0.1 mg/ml LF) in the
presence of 0.1% DMSO or 10 mg/ml MG-132 (EMD Chemicals,
Gibbstown, NJ) for 24 h. Total cell lysates were collected and
subjected to immunoblotting. To determine whether MKK7 was
cleaved by LF in mammalian cells, 293FT cells were treated with
PA alone (1 mg/ml PA) or LeTx (1 mg/ml PA plus 0.1 mg/ml LF)
for 24, 48, and 72 h. Total cell lysates were collected and subjected
to immunoblotting.
In vitro kinase assay
To test the kinase activity of MEK and MEKcr, V5-MEK
fusion proteins were first immunoprecipitated from SK-MEL-28
stable cell lines as following described. Cells cultured for 24 h were
harvested and lysed on ice in lysis buffer (20 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 2 mM EGTA, 1%
Triton X-100, 2 mM DTT, 10 mM NaF, 1 mM Na3VO4, and
12 mM b-glycerophosphate). Cell lysates were then homogenized
by sonication in ice bath, and 200 mg of total lysates were
incubated with 25 ml of agarose-immobilized V5 antibody (Bethyl
Laboratories, Montgomery, TX) in a total volume of 500 mlo f
lysis buffer on a rotator in 4uC for 12 h. The precipitates were
then washed twice with the lysis buffer and twice with kinase assay
buffer (25 mM Tris-HCl pH 7.5, 5 mM b-glycerophosphate,
2 mM DTT, 0.1 mM Na3VO4, and 10 mM MgCl2), and
resuspended in 50 ml of kinase assay buffer as the kinase source
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cipitate was incubated on ice with or without 0.1 unit of active B-
Raf (Upstate Biotechnology, Lake Placid, NY) or 0.1 mgo f
recombinant ERK2. Assay dilution buffer (20 mM MOPS
pH 7.2, 25 mM b-glycerolphosphate, 5 mM EGTA, 1 mM
Na3VO4 and 1 mM DTT) was added to a total volume of 7 ml,
and then 3 ml of ATP mixture [0.5 mlo f[ c-32P] ATP (10 mCi/
ml, 3000 mCi/mmole; Amersham, Piscataway, NJ) in 250 mM
ATP and 37.5 mM MgCl2] was added. In vitro phosphorylation
reaction was carried out by incubating the reaction in 30uC for
30 min, and then stopped by addition of 10 mlo f2 6SDS sample
buffer. The proteins were then separated in 10% Tris-Glycine gels,
and ERK2 phosphorylation was visualized by using a FLA-5000
PhosphoImager (Fujifilm Corp., Greenwood, SC). The input of
5 ul of V5-fusion proteins was shown by immunoblotting using V5
antibody.
Immunoblotting
Total cell lysates were collected in RIPA lysis buffer. Protein
concentrations were determined using a BCA
TM Protein Assay Kit
(Pierce, Rockford, IL). Five micrograms of total cell lysates were
separated in 10% NovexH Pre-Cast Tris-Glycine Gels (Invitrogen,
Carlsbad, CA) and then electro-transferred onto polyvinylidene
fluoride (PVDF) membranes (Millipore, Billerica, MA) according
to the manufacturers’ instructions. Membranes were then soaked
in 5% non-fat milk for 1 hour and hybridized with primary
antibodies against V5 epitope (Bethyl Laboratories, 1:10,000
dilution for CHO K1 cleavage assays and 1:5,000 dilutions for
SK-MEL-28 stable expressions), NH2-terminus of MEK1 (Milli-
pore, Billerica, MA, #07-641, 1:2,000 dilution), COOH-terminus
of MEK1 (Santa Cruz Biotechnology, Santa Cruz, CA, #SC-219,
1:200 dilution), COOH-terminus of MEK2 (Santa Cruz Biotech-
nology, #SC-525, 1:200 dilution), COOH-terminus of MKK3
(Santa Cruz Biotechnology, #SC-961, 1:1,000 dilution), COOH-
terminus of MKK6 (Epitomics, Burlingame, CA, #1821-1,
1:1,000 dilution), COOH-terminus of MKK7 (Epitomics,
#1949-1, 1:1,000 dilution), phosphp-MEK1/2 (Cell Signaling,
Danvers, MA, #9154, 1:1,000 dilution), phospho-ERK (Cell
Signaling, #9106, 1:2,000 dilution), ERK (Cell Signaling, #9102,
1:1,000 dilution), a-tubulin (Sigma, St. Louis, MO, #T9026,
1:5,000 dilution), b-tubulin (Sigma, #T5201, 1:1,000 dilution), b-
actin (Sigma, #A1978, 1:5,000 dilution), or GAPDH (Cell
Signaling, #2118, 1:5,000 dilution). Conditions for primary
antibody hybridizations were followed according to the antibody
datasheets. After primary antibody hybridization, membranes
were washed three times in TBST buffer (50 mM Tris, 150 mM
NaCl, and 0.1% Tween-20), hybridized with HRP-conjugated
secondary antibodies (Kirkegaard & Perry Laboratories, Gaithers-
burg, MD) according to the instructions of the antibodies, and
then washed three times in TBST buffer. Immunoblotting signals
were then detected by LumiGLO
TM Reagent and Peroxide (Cell
Signaling, Beverly, MA).
Human cDNA Microarray and transcriptional signature
analysis
Two sets of parental SK-MEL-28 cells and cells stably
expressing V5-lacZ, V5-MEK1, V5-MEK1cr, V5-MEK2, or V5-
MEK2cr were treated with LeTx (1 mg/ml PA plus 10 ng/ml LF)
or control (1 mg/ml PA plus 10 ng/ml LF_E687C) for 24 h. Total
cell lysates were prepared from cells in one of the two sets and
subjected to immunoblotting to examine individual MEK1 or
MEK2 signaling (see Figure S1). Total RNA samples were
prepared from cells in the other set by using mirVana
TM RNA
isolation kit (Applied Biosystems, Austin, TX). Four RNA samples
(control-treated V5-lacZ-expressing cells, LeTx-treated V5-lacZ-,
V5-MEK1cr, and V5-MEK2cr-expressing cells) were submitted to
the Microarray Core Laboratory at the Van Andel Research
Institute for microarray hybridization. A total of three indepen-
dent experiments were performed. Gene expression profiles
(n=12) were generated using the Agilent 60-mer Whole Human
Genome 44 k Microarray platform according to the manufactur-
er’s instructions. All subsequent analysis was performed using the
Bioconductor software environment. Microarray data was pro-
cessed and normalized using the limma Bioconductor package
[49,50]. Microarray data is MIAME compliant and the raw data
has been deposited in the GEO database (GEO accession number:
GSE23930). Gene set enrichment analysis was then performed
using the PGSEA Bioconductor package [35] with only the most
significant results shown. A signature was determined to be
uniquely rescued by V5-MEK1cr or V5-MEK2cr when it satisfied
two criteria. First, the signature in V5-lacZ-expressing cells had to
have a highly significant (p,0.005) positive or negative response to
LeTx treatment while in cells expressing V5-MEK1cr or V5-
MEK2cr showed a highly significant (p,0.005) response to LeTx
treatment in the opposite direction. Second, the signature in cells
expressing the other V5-MEKcr isoform did not demonstrate a
highly significant (p,0.005) to LeTx treatment. Differentially
expressed genes were identified using a moderated t-statistic as
implemented in the limma Bioconductor package. Significance
values were adjusted using the false discovery rate (FDR) method
to compensate for multiple testing.
In vitro proliferation assay
SK-MEL-28 cells (1,500 cells) were cultured in 96-well plates for
24 hours, and then treated with control (1 mg/ml PA) or LeTx
(1 mg/ml PA plus 0.01–10,000 ng/ml LF) for 72 hours. For
U0126 and PD 184352 treatments, cells were treated with 1–
100,000 nM U0126 (EMD Chemicals, Gibbstown, NJ) or 0.01–
10,000 nM PD 184352 (USBiological, Marblehead, MA) for 72 h.
Cell viability was determined by using CellTiter 96H Aqueous
Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI)
according to the manufacturer’s instructions. LeTx-induced
growth inhibition on each stable cell line was presented by
plotting the relative viability normalized with PA control treatment
against LF concentrations. IC50 values were determined by
SigmaPlot software (Systat Software, San Jose, CA). Statistical
analysis of data was performed by one-way ANOVA (www.
physics.csbsju.edu/stats/anova_NGROUP_NMAX_form.html)
followed by post-hoc analysis (http://graphpad.com/quickcalcs/
posttest1.cfm).
Anchorage-independent growth assay
Anchorage-independent growth assays were performed as
described [46]. Briefly, 10,000 cells were prepared as single cell
suspensions in 0.35% agar prepared in a volume of 1 ml of culture
media, and then seeded onto 1 ml of hard agar (1% agar prepared
in culture media) in 12-well plate. One day after cell seeding, 1 ml
of culture media containing PA along control (1 mg/ml PA) or
LeTx (1 mg/ml PA and 0.01 mg/ml LF) were added on the top of
cell-containing agar layer. Cells were then incubated at 37uCi na
humidified 5% CO2 incubator. The PA- or LeTx-containing
culture media was replaced every 2–3 days for a total of 21 days.
Colonies were then fixed and stained with 1% crystal violet in 10%
ethanol for observation. Images were then taken under a dissecting
microscope. Colonies .50 mm in diameter were quantified using
Imagine software as previously described [46]. Colony density was
normalized to control untreated samples.
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Figure S1 Individual MEK1 or MEK2 in SK-MEL-28
cells. Two sets of SK-MEL-28 parental cells and the cells stably
expressing V5-lacZ, V5-MEK1, V5-MEK1cr, V5-MEK2, or V5-
MEK2cr were treated with PA plus LF_E687C control (EC) or
LeTx (LF) for 24 h as described in Material and Methods. Total
RNA samples were collected from one of the two sets of cells, and
subjected to cDNA microarray hybridization and data analysis.
Total cell lysates were collected from cells in the other set for
immunoblotting probed with antibodies against V5 epitope (top
panel), NH2-terminus of MEK1 (the second panel), NH2-terminus
of MEK2 (the third panel), phospho-ERK1/2 (the fourth panel),
total ERK1/2 (the fifth panel), and GAPDH (bottom panel).
(TIF)
Figure S2 Expression levels of V5 fusion proteins in SK-
MEL-28 cells. SK-MEL-28 cells stably expressing V5-lacZ, wild-
type V5-MEK or V5-MEKcr were established as described. Total
cell lysates were harvested and subjected for immunoblotting by using
antibody against V5 epitope to detect expression levels of V5 fusion
proteins (upper panel) and antibody against a-tubulin for equal
loading control (lower panel). Parental SK-MEL-28 cells (P) and cells
stably expressing V5-lacZ (Z) were used as controls. High (H),
moderate(M)andlow(L)expressionlevelsofV5-MEKareindicated.
(TIF)
Figure S3 Sensitive of SK-MEL-28 stable cells to LeTx in
vitro. SK-MEL-28 parental cells (A, solid line) and the cells stably
expressing V5-lacZ( A, dashed line), V5-MEK1 (B, green lines),
V5-MEK1cr (B, red lines), V5-MEK2 (C, green lines) or V5-
MEK2cr (C, red lines) with different V5-fusion protein expression
levels: low (B and C, dashed lines), moderate (B and C, thin solid
lines) or high (B and C, thick solid lines) were tested for the
sensitive to LeTx by doing a in vitro proliferation assay in the
presence of LeTx as described. The x-axis represents relative
viability normalized by PA alone-treated control. The y-axis
represents the concentration of LF. Data presented in this figure is
a representative of three independent experiments. Error bars
represent standard divisions of triplicate wells in the assay.
(TIF)
Figure S4 Sensitivity of SK-MEL-28 stable cell stably
expressing V5-MKK3cr or V5-MKK6cr to LeTx in vitro.
SK-MEL-28 parental cells, cells stably expressing V5-lacZ, and cells
stably expressing low (L), moderate (M), or high (H) levels of V5-
lacZ, wild-type V5-MKK, or V5-MKKcr (indicated) were tested for
their sensitivity to LeTx as described in Materials and Methods.
Results are presented as described in the legend of Figure 8. One-
way ANOVA followed by post-hoc analysis on all the 26 clones
(presented in Figure 8 and here) showed that only the V5-
MEK2cr(M), V5-MEK2cr(H), and V5-MKK6cr(L) have statistical-
lyhigherIC50valuescomparedtotheparentalline,withpvaluesless
than 0.003, 0.00001, and 0.05, respectively (the p value for the V5-
MKK6(H)clonewas.0.05).However,wearereluctanttoconclude
that expression of V5-MKK6cr protects SK-MEL-28 cells from the
effect of LeTx because the increased resistance was not observed in
other clones expressing moderate or high V5-MKK6cr levels.
(TIF)
Table S1 Transcriptional signatures that are down-
regulated by LeTx treatment and significantly rescued
by MEK2cr.
a t-statistics were obtained from three independent
microarray experiments, and the scores in MEK1cr-expressing
cells have p values greater than 0.005.
b MSigDB Gene Sets:
http://www.broadinstitute.org/gsea/msigdb/search.jsp; GO (Gene
Ontology): http://www.geneontology.org/; Cancer gene modules:
http://robotics.stanford.edu/,erans/cancer/browse_by_modules.
html
(DOCX)
Text S1 Supplemental note
(DOCX)
References S1 Supplemental References
(DOCX)
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